HC Wainwright Issues Pessimistic Estimate for CAPR Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Capricor Therapeutics in a research note issued on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.57) per share for the quarter, down from their previous estimate of ($0.52). HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.23) EPS and FY2026 earnings at ($0.88) EPS.

Several other research analysts also recently commented on the company. Piper Sandler restated an “overweight” rating and set a $20.00 price objective on shares of Capricor Therapeutics in a report on Friday, July 11th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Roth Capital reduced their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, July 14th. Finally, B. Riley assumed coverage on Capricor Therapeutics in a report on Thursday, June 26th. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.56.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $7.78 on Thursday. The business’s 50 day moving average price is $9.29 and its 200-day moving average price is $11.03. The company has a market cap of $355.70 million, a price-to-earnings ratio of -4.74 and a beta of 0.59. Capricor Therapeutics has a fifty-two week low of $3.84 and a fifty-two week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth $183,000. Geode Capital Management LLC boosted its position in shares of Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Invesco Ltd. boosted its position in shares of Capricor Therapeutics by 20.5% in the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Capricor Therapeutics by 1,029.7% in the 4th quarter. Legal & General Group Plc now owns 30,783 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 28,058 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.